3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Liposarcoma
1
Leiomyosarcoma
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Interventions
Imatinib Mesylate
4
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
saracatinib
1
pembrolizumab
1
pazopanib
1
envafolimab
1
TTI-621
1
Sunitinib
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Radiation Dose Hypofractionation
1
Quality of Life
1
Polymerase Chain Reaction
1
Neoadjuvant Therapy
1
MLN 8237
1
Ipilimumab
1
Gene Expression Profiling
1
Dexrazoxane
1
Dactinomycin
1
Blotting, Western
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Dermatofibrosarcoma
×
TTI-621
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts